Overview
Targeting EGFR Mutation-positive NSCLC: Critical Advances in Care
NSCLC Flipbook
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
New developments in the role of mutations in the epidermal growth factor receptor (EGFR) gene are transforming the understanding of how NSCLC progresses as a disease. This insight has enabled NSCLC to evolve from an untreatable disease to one where a number of novel therapeutic options are available, and individualized treatment regimens are now offered to optimize care.
This digital flipbook includes pertinent data and video insights into new and practice-changing therapy in the setting of epidermal EGFR mutation-positive NSCLC. Discussion topics include first-line therapy selection, mechanisms of resistance to EGFR TKIs, EGFR TKI therapy beyond progression, and third-generation EGFR TKIs under investigation.
This is a targeted activity for physicians to learn about and be updated on new and emerging TKI agents for treatment of NSCLC in the first-, second- and third-line based on the most recent data.
The management of patients with EGFR mutation-positive NSCLC is challenging given the increasing number of EGFR TKIs and inevitable acquired resistance due to genetic alterations. Further, there is an increasing amount of clinical trial data with available and emerging therapies that will impact current clinical practice. Clinicians require up-to-date knowledge of these data to facilitate application in clinical practice and guide the selection of initial frontline and sequential therapies.
Upon completion of this activity, participants will be able to:
• Select personalized first-line therapy for patients with EGFR mutation-positive NSCLC based on clinical factors and molecular subtyping (Knowledge, Competence, Performance)
• Discuss mechanisms of acquired resistance to EGFR TKI therapy and evidenced-based approaches for selection of sequential therapy in these patients (Knowledge, Competence)
• Interpret emerging clinical trial efficacy and safety data that will inform application of EGFR TKIs, including comparator trials, novel agents, and combination regimens (Knowledge, Competence, Performance)
• Select personalized first-line therapy for patients with EGFR mutation-positive NSCLC based on clinical factors and molecular subtyping (Knowledge, Competence, Performance)
• Discuss mechanisms of acquired resistance to EGFR TKI therapy and evidenced-based approaches for selection of sequential therapy in these patients (Knowledge, Competence)
• Interpret emerging clinical trial efficacy and safety data that will inform application of EGFR TKIs, including comparator trials, novel agents, and combination regimens (Knowledge, Competence, Performance)
Sponsored by the University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Pfizer, Inc.
• Physicians will be better aware, informed and equipped to optimally treat NSCLC patients with mutations in the EGFR tyrosine kinase domain, thus enabling them to achieve better response rates and progression free survival rates. (Knowledge, Competence)
• Knowledge of the patient populations, clinical trial designs, and efficacy and safety data from available and ongoing trials can facilitate physicians to apply the use of the TKIs in clinical practice. (Knowledge, Competence, Performance)
• Physicians will be both informed and thus able to make clinical decisions for developing personalized patient treatment regimens from a number of potential therapies for patients with EGFR mutation-positive NSCLC, including combination therapy with checkpoint inhibitors. (Knowledge, Competence, Performance)
• Knowledge of the patient populations, clinical trial designs, and efficacy and safety data from available and ongoing trials can facilitate physicians to apply the use of the TKIs in clinical practice. (Knowledge, Competence, Performance)
• Physicians will be both informed and thus able to make clinical decisions for developing personalized patient treatment regimens from a number of potential therapies for patients with EGFR mutation-positive NSCLC, including combination therapy with checkpoint inhibitors. (Knowledge, Competence, Performance)
George R. Simon, MD, FACP, FCCP
Professor of Medicine
Department of Thoracic Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Professor of Medicine
Department of Thoracic Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
Web Editor, JAMA Oncology
Founder & President
GRACE: Global Resource for Advancing Cancer Education
Seattle, WA
The Accreditation Council for Continuing Medical Education has announced standards and guidelines to ensure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.
The University of Texas MD Anderson Cancer Center has, through a formal review process, made every attempt to resolve all potential conflicts of interest prior to this activity. For information on this process, please contact the CME/Conference Management at 713/792-5357.
The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
FACULTY | COMMERCIAL INTEREST |
George Simon, MD, FACP, FCCP | Grant research support: Merck; Paid consultant: Takeda, Merck; Membership on advisory committees: RefleXion, Genprex |
Howard (Jack) West, MD | Paid consultant: AZ, Genentech.Roche; Speaker's Bureau: AZ; Membership on advisory committees: Genentech.Roche |
PLANNING COMMITTEE MEMBERS | COMMERCIAL INTEREST |
George Simon, MD, FACP, FCCP | Grant research support: Merck; Paid consultant: Takeda, Merck; Membership on advisory committees: RefleXion, Genprex |
Howard (Jack) West, MD | Paid consultant: AZ, Genentech.Roche; Speaker's Bureau: AZ; Membership on advisory committee: Genentech.Roche |
CME ACTIVITY REVIEWERS/APPROVERS | COMMERCIAL INTEREST |
Dan Gombos, MD | Paid consultant: Abbvie; Other relevant financial or material interests: Aura Biosciences, 3T Biosciences |
The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
PLANNING COMMITTEE MEMBERS
CME ACTIVITY REVIEWERS/APPROVERS
PLANNING COMMITTEE MEMBERS
Angie Castillo | Katlyn Cooper | Arman Nabatiyan, PhD | Greg Paladino |
Diane C. Bodurka, M D, BS, MPH | Larry Driver, MD | David Followill, PhD |
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.